Plain-English translation of NCT07556640 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment approach for advanced stomach cancer that has spread to the peritoneum (the lining inside the abdomen). The study combines three medications: LM-302, S-1, and intraperitoneal paclitaxel (a chemotherapy drug delivered directly into the abdomen). Some patients will also receive cadonilimab, an immunotherapy drug designed to boost the body's immune system to fight the cancer.
Stomach cancer that spreads to the abdomen is very serious and difficult to treat. Researchers believe that combining this immunotherapy medication with chemotherapy may help patients live longer and have better outcomes than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
You would receive the combination of medications according to a treatment schedule overseen by the study team. Some of the chemotherapy is delivered directly into your abdomen, while other medications are taken by mouth or given intravenously. You will have regular clinic visits for blood tests, physical exams, and imaging scans to monitor how well the treatment is working and manage any side effects. The study will track your health and treatment response over time.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China